You are here

Valchlor (Mechlorethamine) Antifungal Gel Launched in U.S.

First FDA-approved topical formulation of mechlorethamine (November 18)

Valchlor (Actelion Ltd.), the first FDA-approved topical formulation of mechlorethamine (commonly known as nitrogen mustard), is now available for patients in the U.S.

The gel, which is applied topically once a day, is an alkylating drug indicated to treat patients with stages IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) who have received prior skin-directed therapy.

Valchlor (mechlorethamine) gel 0.016% will be distributed in the U.S. by Accredo Specialty Pharmacy.

Mycosis fungoides is the most common type of cutaneous T-cell lymphoma, a rare form of non-Hodgkin's lymphoma. In the U.S., approximately 20,000 patients are currently diagnosed with stage IA-IB MF-CTCL, qualifying it as a rare or orphan disease.

Source: Actelion Ltd.; November 18, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress